Last reviewed · How we verify
NNC0472-0147
At a glance
| Generic name | NNC0472-0147 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NNC0472-0147 CI brief — competitive landscape report
- NNC0472-0147 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI